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Abstract
Background: Oncogenic g-herpesviruses establish life-long infections in their hosts and control of these latent
infections is dependent on continual immune surveillance. Immune function declines with age, raising the
possibility that immune control of g-herpesvirus infection becomes compromised with increasing age, allowing
viral reactivation and/or increased latent load, both of which are associated with the development of malignancies.
Results: In this study, we use the experimental mouse g-herpesvirus model, gHV68, to investigate viral immunity in
aged mice. We found no evidence of viral recrudescence or increased latent load in aged latently-infected mice,
suggesting that effective immune control of g-herpesvirus infection remains intact with ageing. As both cellular
and humoral immunity have been implicated in host control of gHV68 latency, we independently examined the
impact of ageing on gHV68-specific CD8 T cell function and antibody responses. Virus-specific CD8 T cell numbers
and cytolytic function were not profoundly diminished with age. In contrast, whereas ELISA titers of virus-specific
IgG were maintained over time, there was a progressive decline in neutralizing activity. In addition, although aged
mice were able to control de novo acute infection with only slightly delayed viral clearance, serum titers of
neutralizing antibody were reduced in aged mice as compared to young mice.
Conclusion: Although there is no obvious loss of immune control of latent virus, these data indicate that ageing
has differential impacts on anti-viral cellular and humoral immune protection during persistent gHV68 infection.
This observation has potential relevance for understanding g-herpesvirus immune control during disease-associated
or therapeutic immunosuppression.
Background
Ageing impacts many aspects of mammalian biology,
including immune function [1]. Immunological ageing is
associated with a decline in the production of naïve T
and B cells, defects in the production of high-affinity
antibodies, and impaired CD4 T cell function [2-5]. As a
consequence, the elderly exhibit a reduced responsive-
ness to vaccination and an increased susceptibility to
newly encountered pathogens. Although not thoroughly
studied, there are also data to suggest that ageing may
dampen immune control over chronic viral infections.
For example, the increased incidence of herpes zoster
disease in the elderly is believed to be due in part to the
waning of cell-mediated immune control over dormant
varicella (chicken pox) virus reactivation [6].
The human g-herpesviruses, Epstein-Barr virus (EBV)
and Kaposi’s sarcoma-associated herpesvirus (KSHV), are
important pathogens that establish life-long latency in
infected individuals and are associated with a wide variety
of malignancies, including Burkitt’s lymphoma, Hodgkin’s
disease, nasopharyngeal carcinoma, Kaposi’s sarcoma, and
B cell lymphoproliferative syndromes [7]. Most of the
malignancies develop after years of viral dormancy, and
are accompanied or triggered by viral reactivation [8]. An
important role for immune control in preventing the
development of malignancies is illustrated by the fact that
immunosuppression, as a consequence of disease or sup-
pressive immunotherapy, leads to the development of
EBV-associated lymphoproliferative syndromes and
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It is difficult to directly assess the age-associated onco-
genic consequences of diminished immune control of the
g-herpesviruses, as the development of malignancies asso-
ciated with g-herpesvirus infection is a multistep process.
In order to directly assess the impact of ageing on the
ability to maintain control of the g-herpesviruses, we
have employed the well-characterized, experimental mur-
ine g-herpesvirus infection model, in which we can kine-
tically monitor several aspects of immune function.
Murine g-herpesvirus gHV68 (MHV-68 or murid herpes-
virus-4) has significant structural and biological similari-
ties to the two human herpesviruses, EBV and KSHV,
and is emerging as an important experimental model for
studying basic mechanisms of immune control of g-her-
pesviruses in an easily manipulated animal system
[10-14]. Intranasal administration of gHV68 to mice
establishes an acute lytic infection in lung epithelial cells,
which is normally controlled by day 13 postinfection via
the anti-viral activities of CD4 and CD8 T cells [11,12].
Latency is established in the lung, concurrent with the
lytic infection [15], and is subsequently established in
splenic B cells, macrophages and dendritic cells [16-18].
Latent virus persists for the lifetime of the host, and is
kept from reactivating to produce detectable levels of
lytic virus by both cellular and humoral mechanisms of
immune control [11,12,19]. Constant immunosurveil-
lance is critical, as immunosupression leads to recrudes-
cence of lytic virus in gHV68-infected mice.
I nt h ec u r r e n ts t u d yw ee x p e r i m e n t a l l yi n f e c t e d
C57BL/6 mice intranasally with low doses of gHV68 and
monitored immune control of the virus over time. Spe-
cifically, we assessed latent load, protection against re-
infection, and virus-specific humoral and cellular immu-
nity with increasing time after infection to determine
the impact of ageing on immune control of a latent
infection established during youth. We also examined
the ability of aged mice to control a de novo g-herpes-
virus infection. The data reveal no evidence of viral
recrudescence, or increase in latent viral load, with age-
ing. In addition, aged mice were capable of clearing lytic
virus following de novo gHV68 infection with only
slightly delayed kinetics. However, ageing had a differen-
tial impact on the cellular and humoral components of
immune control. Whereas there was no overall reduc-
tion in virus-specific T cell numbers or function with
age, and virus-specific antibody titers were found to
remain stable, we observed a gradual decline in the neu-
tralizing activity of serum taken from aged latently-
infected mice. In addition, antibodies generated in aged
mice following a de novo infection had impaired neutra-
lizing activity as compared to antibodies generated in
younger mice. Thus, although cellular immunity appears
to be sufficient for the control of latent gHV68 infection
throughout the life of the host, impaired humoral
immunity, as observed with ageing, may have significant
implications for maintaining immune control over g-her-
pesvirus infection following therapeutic or infection-
mediated immunosuppression.
Results
Viral latency is controlled in aged mice
As a first step in determining whether there is an age-
associated decline in immune control of the persistent
g-herpesviruses, we monitored latent viral load in
gHV68-infected mice over time following infection. We
used two independent assays- the limiting dilution PCR
assay (LDA/PCR) which allows determination of the fre-
quency of latently-infected cells [19,20] and the quanti-
tative PCR assay which allows determination of genome
copy number within a standard amount of genomic
DNA [21]. Latency assessed by either method was
shown to decline after the early peak of latency in the
spleen and then stabilize for more than a year after
infection (Figure 1). Consistent with the stable latent
load in aged mice, we failed to detect recrudescent lytic
virus in the lung, spleen or a variety of other anatomical
sites (data not shown). These data suggest that immune
control over gHV68 latency is maintained with age.
Protective immunity is maintained in aged mice
It has been shown that mice latently infected with
gHV68 are protected from a second, homologous viral
challenge [22]. Therefore, as another way of assessing
protective anti-viral immunity in aged gHV68-infected
mice, we tested whether these mice could become re-
infected with homologous virus. Young mice (3 months
Figure 1 gHV68 latency in the spleen remains stable with age.
The reciprocal frequency of latently-infected cells as determined by
LDA/PCR is plotted on the left axis (open circles) and the genome
copy number per 200 ng DNA is plotted on the right axis (closed
circles) over time after intranasal infection with 400 PFU gHV68. The
lines join the means of three individual mice at each timepoint.
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tion) were intranasally challenged with 400 or 3000 PFU
gHV68, and lytic viral titers were monitored in the lung
at 3 and 6 dpi (Figure 2). The data show high viral titers
in young naïve mice at 3 and 6 dpi, as expected. How-
ever, only a low level of viral replication was detected at
3 dpi in the lungs of both young and aged latently
infected mice and the level of viral replication did not
vary with the dose of the challenge inoculum. By 6 dpi,
virus was mostly cleared from the lungs of mice in both
age groups. Similarly, there was no significant increase
in viral titers in the spleens of either young or aged
latently-infected mice after re-infection (data not
shown). Together, the absence of viral recrudescence
with increasing age and the comparable resistance of
young and aged mice to re-infection with homologous
virus suggest that there is no overall loss of immune
control of gHV68 with age.
Virus-specific CD8 T cell numbers are maintained and can
mediate cytotoxicity in aged mice
As it has been shown that both cellular and humoral
immunity contribute to immune control of gHV68
[17,19,23-28], we sought to investigate the impacts of
ageing on the functionality of each arm of the immune
system during viral latency. In order to assess the
impact of ageing on cellular immunity, we determined
the numbers of gHV68-specific CD8 T cells present in
latently-infected mice at different timepoints after infec-
tion using MHC class I tetramers specific for two well-
characterized gHV68 epitopes p56 (ORF6487-495)a n d
p79 (ORF61524-531)(Figure 3). The data show that p56-
and p79-specific CD8 T cells are maintained in latently-
infected mice over time, up to 21 months post infection.
Although occasional individual mice were found to
express higher than normal numbers of tetramer-posi-
tive cells as early as 6 months post infection, in general
we did not observe an age-associated development of
virus-specific T cell inflation as has been described for
CMV infection [29-31], or virus-specific clonal expan-
sions as we had previously observed in Sendai virus-
infected mice [32]. We also assessed the cytolytic activ-
ity of the ORF61-specific CD8 T cells present in
latently-infected mice at various timepoints following
infection using an in vivo CTL assay. As shown in Fig-
ure 4, the cytolytic activity against ORF61-pulsed targets
measured in individual mice remained stable for up to
two years after infection. In addition, in agreement with
a previous report [33], the numbers and CTL function
of gHV68-specific CD8 T cells specific for ORF-6-pulsed
targets were also maintained with age (data not shown).
Virus-specific antibody levels are maintained, but
neutralizing activity declines
We next determined the impact of ageing on humoral
immunity. It has previously been shown that following
Figure 2 Latently-infected aged mice are protected against re-infection by gHV68. Young mice (3 months pi; circles) and aged mice (19
months pi; squares) were intranasally challenged with gHV68 (400 PFU, closed symbols or 3000 PFU, open symbols). Naïve mice were challenged
as a control (triangles). Symbols indicate the titers of lytic gHV68 virus detected in the lungs of individual mice at 3 and 6 dpi. The dotted line
represents the limit of detection for the plaque assay used to measure viral titers. Chi-square analysis comparing numbers of mice with or
without plaques detectable in lungs revealed significant differences (P < 0.05) only between the naïve mice challenged as a control and the
other four groups.
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bodies peak on day 10 and subsequently subside, and
class-switched antibody levels increase over the first 3
weeks of infection and are then maintained at constant
levels for at least 90 days [34,35]. As shown in Figure
5A, we found that the serum titers of virus-specific IgG
were similar between recent (1-3 months p.i.) and long-
term (18-22 months p.i.) latently infected mice. How-
ever, serum neutralization titers were found to be
greatly reduced in the majority of mice 18-22 months
postinfection (Figure 5B). The reduction in neutralizing
activity was an unexpected result, as humoral immunity
has been shown to be remarkably long-lived for other
viruses, including small pox and influenza virus [36-38].
This loss of neutralizing activity with age was specific
for gHV68 infection, as serum antibody titers and
neutralizing activity were maintained long-term in influ-
enza virus-infected mice (1-3 and 18-22 m.p.i; Figure
5C, D). Interestingly, the loss of neutralizing activity was
not restricted to aged mice, rather the decline was gra-
dual over the course of gHV68 infection (Figure 6).
Importantly, the decline in neutralizing titer had func-
tional implications, as passively-transferred sera from
aged gHV68-infected mice was less efficient in protect-
ing naïve mice from de novo gHV68 challenge than sera
transferred from young gHV68-infected mice (Figure 7).
Taken together, whereas we found no defect in T cell
immunity or loss of overall immune control of latency,
there was a clear age-associated change in humoral
immunity over the course of latent gHV68 infection.
Aged mice can control de novo infection
Despite the decline in neutralizing antibody titers, our
data indicate that T cell function is intact and immune
control over gHV68 latency is maintained with ageing.
This observation is consiste n tb o t hw i t ho u rp r e v i o u s
finding that T cells can control reactivation in the
absence of neutralizing antibodies [19] and the notion
that T cell memory generated when young retains func-
tion into age [39,40]). However, de novo infection in the
absence of CD4 help has been shown to generate defec-
tive CD8 T cell memory [41-43], and the degree of CD4
dependence may vary with the pathogen. Specifically for
gHV68, it has been shown that CD4-deficient mice are
able to clear lytic virus and viral latency is established
normally, however these mice progressively lose immune
control over viral latency resulting in recrudescence of
lytic virus around 42 dpi [17]. Because there is a well-
established age-associated decline in CD4 T cell func-
tion [44-49], we examined the ability of aged naïve mice
to control de novo infection as another measure of the
impact of ageing on functional gHV68-specific immu-
nity. The data show that clearance of lytic virus from
the lungs was only slightly delayed (not statistically sig-
nificant) in aged mice compared to young mice follow-
ing the initial infection (Figure 8) and that comparable,
stable levels of latent virus were detected in the spleens
of both groups of mice, as assessed by both infective
center and genome copy assays (Figure 9). However,
analysis of gHV68-specific CD8 T cell responses elicited
in infected mice using MHC class I tetramers revealed
generally reduced numbers of virus-specific p56 and p79
CD8 T cells in aged compared with young mice after de
novo infection (Figure 10).
Analysis of virus-specific serum antibody titers at 15,
30 and 60 dpi showed that although titers of virus-speci-
fic IgM were comparable in young and aged mice early
after infection (days 15 and 30), virus-specific IgM titers
w e r ei n c r e a s e di na g e dm i c ea t6 0d p i( F i g u r e1 1 A ) ,
consistent with an age-associated deficiency in the
Figure 3 Virus-specific CD8 T cell numbers are maintained with
age. Mice were bled at various times following gHV68 infection and
virus specific CD8 T cells were detected using MHC class I tetramer
staining and flow cytometry. Symbols represent the frequency of
ORF6487-495 (p56, upper panel) and ORF61524-531 (p79, lower panel)
specific cells among CD44
high CD8
+ T cells found in the peripheral
blood of individual mice at the indicated times post infection.
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Page 4 of 14Figure 4 Virus-specific CD8 T cells present in latently-infected mice retain CTL function with age. Cytolytic activity of ORF61-specific CD8
T cells was measured at the indicated times post infection using a 16-17 h (Panel A) or a 4 h (Panel B) in vivo CTL assay as described in the
Materials and Methods. Symbols represent specific killing calculated for individual mice. Bars indicate the medians calculated from data compiled
from three independent experiments. Significance was assessed using the Mann-Whitney rank test (two-tailed, 95% confidence).
Figure 5 Serum titers of gHV68-specific antibody are maintained in latently infected mice with age, but serum neutralization activity
wanes. The titers of virus-specific IgG were measured in the serum of latently-infected young (1-3 months p.i.) and aged (18-22 months p.i.) by
ELISA (Panel A). Neutralization activity (measured in the same sera samples as A) were determined using an in vitro neutralization assay (Panel B).
As a control, antibody titers (C) and neutralization activity (D) were measured in serum taken from mice (young and aged, as above) previously
infected with influenza virus ×31. Symbols represent serum antibody titers and neutralization activities measured for individual mice. Bars
indicate the medians calculated from the data shown. Significance was assessed using the Mann-Whitney rank test (two-tailed, 95% confidence).
Ns; not significant.
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examined (Figure 11B). In addition, serum neutralization
titers were significantly compromised in aged mice at all
timepoints examined (Figure 11C). Taken together,
despite statistical differences in cellular and humoral
immunity after infection of aged compared with young
mice, the aged mice were able to control infection com-
parably to young mice (Figures 8 and 9).
Discussion
The impaired ability of the elderly to control acute pri-
mary virus infections is well-characterized, whereas less
is known about the impact of age-associated decline in
immunity in control of latent, persistent and/or chronic
viruses. Here we have exploited a robust and well-charac-
terized mouse g-herpesvirus model to show that there is
no overt loss of immune control of latent virus with age-
ing. The experimental mouse model has allowed us to
separately dissect the impact of ageing on cellular and
humoral mechanisms of immune control. Interestingly,
the data show differential impacts of ageing on cellular
and humoral immunity- numbers and function of virus-
specific CD8 T cells were maintained, whereas there was
a progressive decline in viral neutralizing activity, despite
maintenance of virus-specific antibody titers.
The impact of ageing on the immune control of the
human g-herpesviruses has not been well-studied. One
report showed increased numbers, but decreased func-
tion, of CD8 T cells specific for an immunodominant
EBV epitope [50], and another report showed higher
levels of reactivation with ageing [51]. A third report
showed increased anti-viral antibodies in the elderly,
consistent with enhanced reactivation [52]. Initially,
these data appear to be in contrast to our results using
the gHV68 mouse model, in which we showed no
decline in cellular immune control of gHV68 and no
reactivation or increased latent load with ageing. How-
ever, despite anecdotal reports of declining immune
control of EBV with ageing cited above, a strong corre-
lation between ageing and human g-herpesvirus-asso-
ciated malignancies has not been demonstrated. There
are a few notable exceptions- the age-associated devel-
opment of non-HIV-associated Kaposi’s sarcoma [9], the
bimodal age distribution of EBV-associated Hodgkin’s
Disease with an increased frequency among the elderly
Figure 6 Neutralizing titers of gHV68 decline progressively with time after infection. Serum titers of gHV68-specific IgG (closed triangles)
and neutralizing antibody (open circles) were measured in individual mice at the indicated months post infection. Symbols represent the mean
reciprocal titers (log10), ± standard deviation, calculated at each timepoint (≥ 8 mice analyzed per timepoint). A linear regression was performed
analyzing time versus reciprocal titer for virus-specific IgG or neutralizing antibody. The slope for virus specific IgG did not differ significantly
from zero (p = 0.6780), however the slope for virus neutralizing antibody did (p = 0.0085).
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Figure 7 Sera from aged mice is less protective in vivo against
acute gHV68 infection. One hundred microliters of sera from
young (3 months p. i.) or aged (22 months p. i.) gHV68-infected
animals was injected intravenously into naïve C57BL/6 mice one day
prior to intranasal gHV68 infection (400 PFU). Control mice received
convalescent sera from influenza virus-infected mice. Symbols
represent lung viral titers measured in individual mice at 5 days
post infection using a standard plaque assay. Bars indicate the
medians calculated from the data shown. Significance was assessed
using the Mann-Whitney rank test (two-tailed, 95% confidence). Ns;
not significant
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Page 6 of 14[53], and a recently-identified, age-related EBV-asso-
ciated B cell lymphoproliferative disorder [54-57]. How-
ever, as EBV infects > 90% of the human population,
one would expect a more dramatic increase in the inci-
dence of g-herpesvirus-associated malignancies in the
elderly if ageing resulted in failure to control viral
latency. Thus, our data in the mouse model showing no
striking loss of immune control of gHV68 with ageing
are consistent with the absence of a strong increase in
g-herpesvirus associated malignancies in man.
However, an important caveat to our studies is that
the experimental mice were maintained under specific
pathogen free conditions during aging. This, of course,
does not reflect the human situation, as humans are
exposed to multiple acute and chronic infections as
they age. It is possible that intermittent stimulation eli-
cited by heterologous infections would disrupt quies-
cent latency and reveal differences in the ability of
young and aged individuals to control the latent infec-
tion. Despite this experimental caveat, our studies in
mice taken together with the observations in humans
suggest that ageing has little effect on the immune
control of g-herpesvirus latency. These data are also
consistent with the idea that T cell memory generated
when young is well maintained [39,40], and with the
data reported here and elsewhere [33] showing that
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Figure 8 Aged mice clear lytic virus from their lungs following de novo gHV68 infection with only slightly delayed kinetics. The titers
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Figure 9 Aged mice are capable of maintaining control over latent virus following de novo gHV68 infection. The levels of latent virus
present in the spleens of gHV68-infected young (3 months old, closed symbols) and aged (19-24 months old, open symbols) mice at the
indicated days post infection were measured using an infective center assay (Panel A) and a genome copy assay (Panel B), as described in the
Material and Methods. The dotted line indicates the limit of detection of the infective center assay. Each symbol represents data obtained from
an individual mouse and bars indicate the means calculated from the data shown.*; P ≤ 0.05 as determined using the Student’s t-test. n.s.; not
statistically significant.
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Page 7 of 14there is no decline in function of gHV68 CD8 T cells
with ageing.
Our conclusion is further supported by the findings that
g-herpesvirus-associated malignancies increase dramati-
cally in instances where immune function is severely com-
promised. Cellular immunosuppression is a frequent
therapy following transplantation or for autoimmune dis-
ease. It is also the consequence of some secondary viral
infections including HIV. Importantly, during cellular
immunosuppression, antibody titers are not immediately
affected and humoral immunity serves as an essential
back-up mechanism. There are several examples of g-her-
pesvirus-associated pathology during immunosuppression.
First, decline in T cell function as a consequence of HIV
infection is attributed to the development of Kaposi’s
sarcoma in KSHV-infected individuals [9]. Second, EBV-
associated lymphoproliferative disease is a well-known
complication of immunosuppressive therapy after stem
cell or solid organ transplantation [58], which is becoming
increasingly frequent in elderly populations. Susceptibility
to develop lymphoproliferative disease following transplant
immunosuppression has been correlated with EBV latent
load or EBV copy number in the latently-infected cell
[59-61]. A specific link between defects in humoral immu-
nity under conditions of impaired cellular immunity is
suggested by the correlation between the development of
Kaposi’s sarcoma in KSHV-infected individuals and
reduced levels of neutralizing antibody [62]. Third, immu-
nosuppressive therapy for autoimmune diseases such as
rheumatoid arthritis and psoriasis, which are prevalent in
the elderly, is frequently complicated by EBV-associated
lymphoproliferative disease and lymphoid neoplasms
[63-65]. Thus, with loss of T cell immunity due to disease
or therapeutic intervention, an impact of ageing on
humoral immunity may have consequences for control of
g-herpesvirus latency.
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Figure 10 Virus-specific CD8 T cells are generated in aged mice following de novo gHV68 infection. MHC class I tetramer staining and flow
cytometric analyses were performed to determine the absolute numbers of ORF6/p56- and ORF61/p79-specific CD8 T cells present in the lungs
(A, B) and spleens (C, D) of C57BL/6 mice infected when young (3 months old, closed symbols) or aged (20 months old, open symbols) at the
indicated days following de novo gHV68 infection. Symbols represent data obtained from individual mice and bars indicate the medians.
Significance was assessed using the Mann-Whitney (two-tailed, 95% confidence). Ns = not significant, * = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001.
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Figure 11 Aged mice produce reduced serum titers of class switched antibody and reduced neutralization titers following de novo
gHV68 infection. Serum titers of gHV68-specific IgM (A) and IgG (B) were measured by ELISA in young (3 months old, closed symbols) and
aged (19-24 months old, open symbols) C57BL/6 mice at 15, 30, and 60 days post infection. (C) The virus neutralization activity of sera at 34, 45,
and 60 days post infection was determined as described in the Materials and Methods. Each symbol represents data obtained from an individual
mouse and bars indicate the medians calculated from the data shown. Statistical significance was determined using the Mann-Whitney test.**; P
≤ 0.01. *; P ≤ 0.05.
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immunity is difficult to detect in the intact host. For
example, in the face of functional cellular immunity,
consequences of a decline in humoral immunity would
not be readily observed. The experimental mouse model
has made it possible to assess the function of the two
arms of adaptive immunity separately. Although CD8 T
cells play a central role in maintaining control of
latency, CD4 T cells and antibody also make important
c o n t r i b u t i o n s[ 1 1 , 1 2 ] .I ti sc l e a rt h a tg-herpesvirus
latency is controlled at multiple levels and that the avail-
ability of a mouse model for analysis of viral control and
anti-viral immunity in ageing mice provides a powerful
experimental approach.
The declining neutralizing activity of gHV68-specific
antibodies with time after infection was an unexpected
result. Despite the short half life (< 3 weeks) of antibo-
dies [66-68], humoral immunity to viruses is usually
long-lived [69,70]. For example, vaccinia-specific anti-
body responses can be identified as long as 75 years
after a single vaccination [71]. The longevity of the anti-
body response is due to the development of long-lived
antibody secreting plasma cells that reside in the bone
marrow [72,73]. These cells have a half-life of ~140
days, and are replenished at a low rate by differentiation
of memory B cells [72]. Recently, it was determined that
survivors of the 1918 influenza virus pandemic had cir-
culating B cells that secreted neutralizing antibodies to
the virus [38]. Our data show a striking decline in the
neutralization activity of gHV68-specific antibodies with
time after infection, despite sustained titers. This is a
novel and unexpected observation, which has significant
implications for ageing immunology research and vacci-
nation strategies, and merits further study. Changes in
EBV-specific antibodies throughout latency have been
previously reported. Specifically, there are age-associated
changes in patterns of specificity of anti-EBV antibodies
[74], that have been shown to correlate with changes in
the latent state of the virus [75]. Titers of EBV antibo-
dies to some epitopes are maintained or increase with
age, but the antibodies are of low avidity and function
poorly [52]. It is possible that changes in the expression
of g-herpesvirus epitopes over time, perhaps due to
changes in immune control of latency, would be mani-
fest in changes in antibody specificities. Concerning
gHV68, we hypothesize that the gradual decline in neu-
tralizing activity is either a consequence of changes in
viral gene expression during long-term latency or reflec-
tive of an increased propensity toward viral reactivation
over time, both of which would result in the presenta-
tion of new epitopes to drive de novo antibody
responses. Also, because the progressive decline in neu-
tralizing activity was observed in gHV68-infected mice
and not influenza-infected mice, this phenomenon is
likely associated with the nature of the infection rather
than the biology of ageing.
A defect in the ability of aged individuals to mount an
e f f e c t i v ed en o v oa n t i b o d yr e s p o n s ei sw e l l - d e s c r i b e d
[76-80]. Underlying B cell defects associated with ageing
include decreased germinal center formation, decreased
levels of somatic mutation and the production of poorly
protective antibodies [81-85]. The age-related defects
are dependent largely on defective CD4 T cells rather
than inherent age-associated defects in B cells. For
example, the generation of germinal centers is depen-
dent on CD4 T cell cognate helper function, which is
reduced with age [86]. Our data describing the develop-
ment of sub-optimal humoral immunity following de
novo gHV68 infection of aged mice is consistent with an
age-associated CD4 T cell defect. Interestingly, however,
the CD8 T cell effectors appeared to be fully functional
and did not permit recrudescence of lytic virus as long
as 60 days after infection, in contrast to the results pre-
viously shown for CD4-deficient mice, which cannot
maintain control of the virus and undergo viral recru-
descence as early as 42 days post infection.
Conclusion
We have found that immune control of a latent mouse g-
herpesvirus is not severely impaired with age. In addition,
aged mice can control a de novo gHV68 infection with
only slightly delayed viral clearance, and maintain control
of latency. These data are consistent with the lack of an
increased incidence of g-herpesvirus-associated malig-
nancies in the elderly. However, immunosuppression of
the elderly is clearly correlated with increased onset of
malignancies and may reflect consequences associated
with age-related changes in humoral immunity.
Methods
Mice
Young (6-8 weeks) and aged (≥ 18 months) C57BL/6 mice
and B6.SJL-Ptprc
aPepc
b/BoyJ (B6.SJL, CD45.1) congenic
mice were obtained from the Trudeau Institute animal
breeding facility. All mice were housed under specific
pathogen free conditions before and after infection. All
animal procedures were approved by the Institutional
Animal Care and Use Committee at the Trudeau Institute.
Virus Stocks, Infections and Vaccination
Clone WUMS of gHV68 [14] was propagated in NIH-
3T3 cells. Virus titers were determined by plaque assay
on NIH-3T3 cells. Influenza virus A/HK-x31 (×31,
H3N2) was grown, stored, and titrated as described pre-
viously [87]. Female mice were anesthetized with 2,2,2-
tribromoethanol (200 mg/kg) prior to intranasal (i.n.)
infection with 400 PFU gHV68 or 300 EID50 of A/HK-
x31 influenza virus.
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Peripheral blood (100-200 μl), obtained by nicking the
tail, was collected in PBS containing 10 U/ml heparin
(Sigma-Aldrich, St. Louis, MO). Single cell suspensions
from the spleens of individual mice were prepared by
mechanical disruption and straining through nylon
mesh, and lung cells from individual mice were pro-
cessed with collagenase D. Samples were depleted of
erythrocytes by treatment with buffered ammonium
chloride solution. Lymphocytes were enriched from lung
cell suspensions by Percoll gradient centrifugation
(Hogan, 2002) and from spleen cell suspensions by pan-
ning against goat anti-mouse IgG (Jackson ImmunoRe-
s e a r c hL a b o r a t o r i e s ,W e s tG r o v e ,P A ) .I s o l a t e dc e l l s
were incubated with Fc block (BD Biosciences, San Jose,
CA) for 15 minutes on ice, and then stained with PE- or
APC-labeled MHC class I tetramers specific for gHV68
ORF6487-495/D
b or ORF61524-531/K
b for one hour at
room temperature. All tetramers were generated by the
Molecular Biology Core Facility at the Trudeau Institute,
as previously described (Altman, 1996). Tetramer-
labeled cells were then stained with fluorescently-conju-
gated antibodies specific for mouse CD8a and mouse
CD44 (BD Biosciences) for 30 minutes on ice, washed,
and then fixed in 1% paraformaldehyde. Data were col-
lected on a Becton Dickinson FACSCalibur flow cyt-
ometer (BD Biosciences) and then analyzed using
FlowJo software (Tree Star, Inc., Ashland, OR).
Plaque Assay
The concentration of lytic virus in lung tissue was deter-
mined using a standard plaque assay on NIH-3T3
mouse fibroblasts [17]. Lung tissue obtained at various
times post infection was mechanically homogenized and
serial-dilutions of the homogenates were prepared.
Diluted homogenates were incubated on monolayers of
3T3 cells for one hour at 37°C/10% CO2,a f t e rw h i c h
the monolayers were overlaid with carboxymethyl cellu-
lose (Sigma-Aldrich) and incubated again at 37°C/10%
CO2. Six days later, monolayers were fixed with metha-
nol, stained with 8% Giemsa stain, and plaques counted.
Infective Center Assay
The frequency of latently infected cells capable of spon-
taneous in vitro reactivation was assessed using an infec-
tive center assay, as previously described [88]. 10-fold
serial dilutions (in triplicate) of splenocytes starting at
10
6 cells/well were plated onto monolayers of NIH-3T3
mouse fibroblast cells. Monolayers were incubated over-
night at 37°C and then overlaid with carboxymethyl cel-
lulose. Plaques were quantitated 6 days later after
methanol fixation and Giemsa staining. Samples were
also assayed following one cycle of freeze/thaw to deter-
mine the contribution of lytic virus to the overall viral
titers. The number of latently infected cells was then
calculated as the difference between the total number of
infected cells and the number of lytically infected cells.
Limiting-dilution PCR Analysis
The frequency of cells carrying viral genome was deter-
mined using a limiting dilution nested PCR assay (LDA/
PCR) for the gHV68 open reading frame 50 (ORF50)
gene as described [19,89]. Briefly, CD19
+ B cells were
purified from the spleens of infected mice as previously
described [90]. B cells were resuspended in isotonic buf-
fer and starting at 10
4 or 10
5 cells/well, were diluted
with uninfected NIH-3T3 cells, and then transferred
into 96 well plates. Twelve replicate reactions were per-
formed for each cell dilution per experiment. Subse-
quently, the ORF50 gene was amplified from cell lysates
with two rounds of nested PCR. The final PCR product
was electrophoresed on a 3% agarose gel and stained
with ethidium bromide. The reciprocal frequency of
cells carrying viral genome was determined using linear
regression with a 95% degree of confidence.
Determination of genome copy
Genome copy was estimated as previously described
[21], with the following changes. DNA was extracted
from 5 × 10
6 B cells using a DNeasy kit (Qiagen),
according to manufacturer’s protocol. ORF50 gene copy
number was determined for 200 ng of DNA per sample,
using a standard curve quantitation method on an
Applied Biosystems 7500 Real-Time PCR System
(Applied Biosystems, Foster City, CA). Reactions were
run in duplicate, and naïve C57BL/6 splenocyte DNA
was used as a negative control. A low ROX AB Taqman
Gene Expression master mix (Applied Biosystems, Fos-
ter City, CA) was used, providing repeatable detection
of copy numbers as low as 3 per 200 ng of DNA. Pri-
mers, probes, and reaction cycles used are described
[21].
Enzyme-Linked Immunosorbent Assay (ELISA)
Virus specific IgG titers in sera were determined by
ELISA [19]. Nunc ImmunoMaxisorp plates were coated
with purified virions at a concentration of 0.5 μg/well.
Following an overnight incubation at 4°C, plates were
washed with PBS-Tween (0.05%), and subsequently
blocked with PBS/BSA (3%) overnight at 4°C. Dilutions
of sera, starting at 1/20, were prepared in PBS/0.05%
Tween/0.5%BSA and added to the antigen coated plates.
After an overnight incubation at 4°C, virus-specific IgG
was detected using alkaline phosphatase-conjugated goat
anti-mouse IgG antibody (Sigma-Aldrich) and p-nitro-
phenyl phosphate (Sigma-Aldrich). Optical densities
were read at 405 nm using a VMax® microplate reader
(Molecular Devices, Sunnyvale, CA). Serum antibody
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serum giving an OD405 reading at least two times
greater than the normal mouse serum control.
Virus Neutralization Assays
For the gHV68 neutralization assay, virus (10
2 PFU) was
incubated with serial dilutions of heat-inactivated serum
samples in 96-well plates for 1 h at 37°C. Following the
incubation, virus/sera mixtures were transferred to 96 well
flat-bottom plates containing monolayers of 3T3 cells.
After 7 days of incubation at 37°C, 10% CO2,t h em o n o -
layers were fixed and plaque formation revealed by staining
with 5% Giemsa stain. Neutralization titers are expressed
as the highest reciprocal dilution of sera required to cause
a 50% reduction in CPE (cytopathic effect).
For the influenza virus neutralization assay, ×31 virus
(100 EID50/well) was incubated with serial dilutions of
heat-inactivated sera, prepared in Zero-Serum media
(Diagnostic Hybrids, Athens, OH) containing 4 μg/ml
trypsin, in 96-well round-bottom plates for 1 h at 37°C.
Following the incubation, virus/sera mixtures were
transferred to 96 well flat-bottom plates containing
monolayers of MDCK cells. Plates were then centrifuged
at 800 × g for 1.5 hrs. Following centrifugation, the
virus/sera mixtures were removed, fresh media added to
each well, and the plates incubated at 33°C, 10% C02 for
14-16 hours. Monolayers were fixed in 80% acetone and
infected cell foci were revealed by incubating with a
combination of biotinylated mouse anti-influenza A
monoclonal antibodies (Millipore, Billerica, MA), alka-
line-phosphatase conjugated goat anti-mouse IgG
(Sigma-Aldrich), and Sigma-Fast BCIP/NBT substrate
(Sigma-Aldrich). Neutralization titers are expressed as
the highest dilution of sera prior to which the number
of foci observed is equivalent to the number of foci
counted in normal mouse sera/virus-only control wells.
Serum transfer
Serum obtained from latent gHV68-infected young (2-4
months post infection) and aged (18-24 months post
infection) C57BL/6 mice was administered intravenously
to young, naive C57BL/6 mice one day prior to intranasal
gHV68 infection (400 PFU). As a control, mice were given
normal mouse serum or convalescent serum obtained
from C57BL/6 mice previously infected with influenza A/
PR8/34 virus (300 EID50). Lungs were harvested from reci-
pient mice on day 5 post infection and viral loads were
measured using the standard gHV68 plaque assay.
In vivo CTL assay
Target splenocytes harvested from B6.SJL (CD45.1
+) con-
genic donor mice were incubated with peptides (10 μg/ml)
at 37°C in 10% CO2 for 5 h with occasional mixing. The
peptides included gHV68 ORF61524-531 and an irrelevant
peptide (either influenza NP366-374 or Sendai NP324-332).
Cells were washed and labeled with 2.5 μMo r≤ 0.5 μMo f
5,6-carboxyfluorescein diacetate succinimidyl ester (CFSE;
Molecular Probes, Eugene, OR) to obtain CFSE
hi
(ORF61524-553)a n dC F S E
low (negative control peptide)
groups. Following CFSE labeling, cells were combined at
equal ratios, washed three times in PBS, and resuspended
at a final concentration of 2 × 10
8 cells/ml. Twenty million
cells (100 μl) were injected intravenously into C57BL/6
mice (CD45.2
+) previously infected with gHV68, or naïve
mice as a negative control. At 4 h or 16-17 h post transfer,
spleens were harvested from recipient mice and single cell
suspensions were prepared for flow cytometric analyses as
described above. The individual populations of peptide-
pulsed donor CD45.1
+ cells present in the spleens of reci-
pient mice were identified and enumerated using a combi-
nation of APC-conjugated antibodies specific for mouse
CD45.1 (eBioscience, San Diego, CA) and CFSE staining
intensity. Percent specific lysis was calculated using the
following formula: [1-(ratio uninfected/ratio infected)] ×
100, where “ratio” refers to the percentage of irrelevant
peptide-pulsed cells divided by the percentage of relevant
peptide-pulsed cells.
Statistical Analyses
Where indicated, groups were compared statistically
using the Student’s t-test, the nonparametric Mann-
Whitney rank test, or linear regression, or the Chi-
square test. P values ≤ 0.05 were considered significant.
All statistical analyses were performed using Prism soft-
ware (GraphPad, La Jolla, CA).
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